
Isomorphic Labs raises $5B Series C in 2026
Isomorphic Labs, the AI drug-discovery company, raised a $5B Series C to push its drug candidates toward clinical trials.
Daily Digest
Daily Digest
Pomegra Startups
Funding rounds, valuations, acquisitions, and IPOs - daily coverage of the companies shaping the private markets

Isomorphic Labs, the AI drug-discovery company, raised a $5B Series C to push its drug candidates toward clinical trials.

French biotech Orakl Oncology raised a $34M Series A for AI-driven predictive oncology using patient-derived tumor models.

Switchpoint Bio (Finland/UK) emerged from stealth with a $5.3M pre-seed to study why patients respond differently to drugs.

Biomatter (Lithuania) raised $18M from Astanor and UVC Partners to build an enzyme lab in Vilnius.

Neurosterix (Switzerland/US) raised $105M to advance experimental treatments for schizophrenia and other neurological conditions.

Neobe (UK) raised €6.1M to engineer bacteria that break down the barriers protecting tumours.

Anaheim Bio (Netherlands) raised €40M to develop a treatment for calcium pyrophosphate deposition disease.

bit.bio (Cambridge, UK), a human cell programming company, closed a $25M Series D for lab-grown human cell models.

Transpharmation (UK) acquired OrganoTherapeutics, a Luxembourg startup building patient-derived brain organoid models.

Samplix, a Danish biotech, secured €25M in the first close of a financing round.

Warhound, a US startup using genetics and cloning to breed military working dogs, raised a $200M seed round.

Swiss biotech Nouscom raised a €120M Series D for its cancer-prevention immunotherapy for Lynch syndrome.